Page 624

Karger_ESC London_2013

22. European Stroke Conference 527 Epidemiology of stroke Plasma HDL as a Predictor of Aspirin Resistance in Stroke Patients: A Cross-Sectional Single Centre Study S. Azmin1, R. Sahathevan2, R. Rabani3, W.Y. Nafisah4, H.J. Tan5, B.B. Hamidon6, S.A. Shamsul7, M.I. Norlinah8 Department of Medicine, UKM Medical Centre, Kuala Lumpur, MALAYSIA1, Department of Medicine, UKM Medical Centre, Kuala Lumpur, MALAYSIA2, Department of Medicine, UKM Medical Centre, Kuala Lumpur, MALAYSIA3, Department of Medicine, UKM Medical Centre, Kuala Lumpur, MALAYSIA4, Department of Medicine, UKM Medical Centre, Kuala Lumpur, MA-LAYSIA5, Department of Medicine, Faculty of Medicine & Health Science, Universiti Putra Ma-laysia, Serdang, MALAYSIA6, Department of Public Health, UKM Medical Centre, Kuala Lumpur, MALAYSIA7, Department of Medicine, UKM Medical Centre, Kuala Lumpur, MALAYSIA8 Background: Aspirin use is known to reduce the recurrence of stroke. However, the clinical response to aspirin has been mixed. A plausible explanation for this may be resistance to the effects of aspi-rin. The causes of aspirin resistance are manifold and multi-factorial. We conducted a study to in-vestigate inherent factors that may predispose towards aspirin resistance in a cohort of aspirin naive stroke patients. Methods: This was a cross-sectional, observational study conducted on patients admitted to our cen-tre with an acute stroke. Fifty consecutive patients were tested for biochemical aspirin resistance us-ing Multiplate platelet analyser after 5 doses of aspirin, corresponding to a total dose of 900mg. Results: Aspirin resistance was present in 14% of our patients. There was an inverse relationship between the presence of aspirin resistance and plasma HDL levels (r=-0.394; p=0.005). No relation-ship was observed between aspirin resistance and total cholesterol, triglycerides, LDL, HbA1c, ALT, ALP, urea and creatinine levels. There were no significant differences in demographic profiles or smoking status between the aspirin-resistant and non-aspirin-resistant groups. Conclusions: The prevalence of biochemical aspirin resistance among our patients was 14%. Our re-sults indicate that a lower HDL level is associated with biochemical aspirin resistance. This may in-crease platelet aggregation and consequently increase the risk of recurrent stroke. The clinical impli-cations for aspirin resistance are far-reaching. Any evidence that correctable factors may negatively influence the action of aspirin warrants further investigation. 624 © 2013 S. Karger AG, Basel Scientific Programme 528 Epidemiology of stroke Comparison of outcomes between acute ischaemic stroke and transient ischaemic attack: data from the ‘Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke’ (TARDIS) tri-al P.M.W Bath1, A Houlton2, K Krishnan3, M Adrian4, N Sprigg5 University of Nottingham, Division of Stroke, Nottingham, UNITED KINGDOM1, University of Nottingham, Division of Stroke, Nottingham, UNITED KINGDOM2, University of Nottingham, Division of Stroke, Nottingham, UNITED KINGDOM3, University of Nottingham, Division of Stroke, Nottingham, UNITED KINGDOM4, University of Nottingham, Division of Stroke, Notting-ham, UNITED KINGDOM5 Background: Patients with TIA (time definition) are expected to have a better outcome and return to normal as compared with ischaemic stroke. We compared baseline characteristics and outcomes for stroke and TIA patients in the UK. Methods: Data from 992 participants (stroke 610, TIA 382) randomised to the on-going TARDIS trial (which compares short-term intensive vs guideline antiplatelet therapy) were assessed. Out-comes at day 90 included dependency (modified Rankin Scale, mRS), disability (Barthel Index, BI), cognitive (t-MMSE, TICS-M), quality of life (EQ-5D), mood (Zung depression scale, ZDS) and re-currence (stroke). Unadjusted and adjusted (age, sex, time since event, previous stroke) comparisons (logistic regression, odds ratio OR and 95% confidence intervals 95% CI relative to TIA, signifi-cant results in bold) were made. Results: Although TIA patients had a better outcome than those with stroke, many did not have nor-mal scores by day 90. Following adjustment, significant difference remained for mRS, BI, t-MMSE, TICS-M and EQ-5D by day 90. There was no significant difference in recurrence rates or mood score between TIA and stroke patients. Conclusion: Although outcome after TIA is better than stroke, many patients do not make a full re-covery. TIA patients may need monitoring of functional outcome, cognition (and mood) to ensure that they receive support where necessary. TIA n (%) Stroke n (%) Unadjusted OR (95% CI) Adjusted OR (95% CI) mRS >1 70 (20.3) 228 (41.8) 0.37 (0.26, 0.49) 0.35(0.25, 0.49) MMSE <16 187 (54.4) 328 (60.1) 0.79 (0.6,1.04) 0.70 (0.52, 0.95) TICS-M <35 183 (53.2) 330 (60.4) 0.74 (0.57, 0.98) 0.65 (0.48, 0.89) EQ-5D <0.8 171 (49.7) 342 (62.6) 0.59 (0.45, 0.77) 0.57 (0.42, 0.77) BI <90 66 (19.2) 155 (28.4) 0.60 (0.43, 0.83) 0.60 (0.42, 0.85) ZDS >17 122 (35.5) 222 (40.7) 0.80 (0.61,1.10) 0.82 (0.61, 1.12) Recurrence 11 (2.9) 18 (3.0) 0.98 (0.46, 2.10) 0.74 (0.33, 1.67)


Karger_ESC London_2013
To see the actual publication please follow the link above